Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 10/31/2025

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 507 publications

Zanubrutinib is active for the treatment of relapsed primary vitreoretinal lymphoma.

Zanubrutinib is active for the treatment of relapsed primary vitreoretinal lymphoma.

Journal: Leukemia & lymphoma
Published: October 17, 2025

Case series - Scrotal edema associated with zanubrutinib.

Case series - Scrotal edema associated with zanubrutinib.

Journal: Canadian Urological Association journal = Journal de l'Association des urologues du Canada
Published: October 08, 2025

Brutons tyrosine kinase inhibitor Zanubrutinib modulates Fc gamma receptors to inhibit platelet destruction for alleviation of refractory immune thrombocytopenia.

Brutons tyrosine kinase inhibitor Zanubrutinib modulates Fc gamma receptors to inhibit platelet destruction for alleviation of refractory immune thrombocytopenia.

Journal: Hematology (Amsterdam, Netherlands)
Published: October 06, 2025

Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma.

Journal: Future oncology (London, England)
Published: October 03, 2025

Clinical analysis of eight patients with lung biopsy-proven pulmonary intravascular large B-cell lymphoma in a single center.

Clinical analysis of eight patients with lung biopsy-proven pulmonary intravascular large B-cell lymphoma in a single center.

Journal: Hematology (Amsterdam, Netherlands)
Published: October 03, 2025

Self-assembled Zanubrutinib-loaded lipid polymer hybrid nanoparticles for enhanced oral absorption by lymphatic uptake: in vitro, ex vivo and in vivo evaluations.

Self-assembled Zanubrutinib-loaded lipid polymer hybrid nanoparticles for enhanced oral absorption by lymphatic uptake: in vitro, ex vivo and in vivo evaluations.

Journal: Pharmaceutical development and technology
Published: September 22, 2025

Efficacy and Safety of Zanubrutinib in the Treatment of Autoimmune Cytopenia Secondary to Indolent B-Cell Lymphoma

Efficacy and Safety of Zanubrutinib in the Treatment of Autoimmune Cytopenia Secondary to Indolent B-Cell Lymphoma

Journal: Zhongguo shi yan xue ye xue za zhi
Published: September 11, 2025

Zanubrutinib in the treatment of Waldenström Macroglobulinemia.

Zanubrutinib in the treatment of Waldenström Macroglobulinemia.

Journal: Future oncology (London, England)
Published: September 11, 2025

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

Real-world treatment patterns of Bruton tyrosine kinase inhibitors in mantle cell lymphoma in a community oncology setting.

Journal: Future oncology (London, England)
Published: September 08, 2025

A Case of Waldenstrom's Macroglobulinemia Presenting as Worsening Neuropathy.

A Case of Waldenstrom's Macroglobulinemia Presenting as Worsening Neuropathy.

Journal: Cureus
Published: September 01, 2025

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.

Zanubrutinib versus acalabrutinib indirect treatment comparison in relapsed or refractory mantle cell lymphoma.

Journal: Leukemia & lymphoma
Published: September 01, 2025

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.

Pirtobrutinib in Chronic Lymphocytic Leukemia: Navigating Resistance and the Personalisation of BTK-Targeted Therapy.

Journal: Cancers
Published: August 15, 2025
Showing 1-12 of 507

Last Updated: 10/31/2025